<DOC>
	<DOCNO>NCT00703911</DOCNO>
	<brief_summary>This study conduct Africa , Europe , Middle-East South America . The primary objective registry observe use single dose multi-dose use activate recombinant human factor VII compare short-term outcome , include effectiveness , safety , quality life treatment satisfaction approve treatment .</brief_summary>
	<brief_title>Observational Registry NovoSevenÂ® Used On-demand Treatment Bleeds Patients With Haemophilia A B With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed haemophilia A B inhibitor Experience mild moderate spontaneous bleeds require ondemand treatment currently prescribe activate recombinant human factor VII Be able willing provide inform consent ( proxy consent caregiver , applicable ) , require local research ethic committee , governmental regulatory authority Be willing provide information least one alternate contact person event patient somehow losttofollowup course registry participation ( applicable patient withdrawn ) Known hypersensitivity active substance excipients formulation activate recombinant human factor VII , mouse , hamster bovine protein</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>